Abstract Number: 0009 • ACR Convergence 2022
Pharmacokinetics, Receptor Occupancy, and Pharmacodynamics of Obexelimab Following Intravenous Administration in Adult Healthy Volunteers and in Patients with Rheumatoid Arthritis
Background/Purpose: Obexelimab is a novel bifunctional antibody that inhibits B-cell, CD19 expressing plasma cell, and plasmablast activity and is expected to provide clinical benefit across…Abstract Number: 1428 • ACR Convergence 2022
Molecular and Clinical Profiling of Rheumatoid Arthritis Patients Predicts the Response to Rituximab
Background/Purpose: Rheumatoid arthritis (RA) is one of the most prevalent rheumatic diseases, mainly characterized by chronically painful, swollen joints that can severely impair physical function…Abstract Number: 0045 • ACR Convergence 2022
Rheumatoid Arthritis Patient-derived Anti-citrullinated Protein Antibodies (ACPAs) Ameliorate Joint Inflammation in Early Collagen-antibody Induced Arthritis (CAIA)
Background/Purpose: ACPAs are present in two-thirds of patients with rheumatoid arthritis (RA) and are associated with higher risks for severe bone erosions. The pathogenic role…Abstract Number: 1572 • ACR Convergence 2022
CD40, BLK and BANK1 in the Pathogenesis of Immunoglobulin-A Vasculitis
Background/Purpose: CD40 is a membrane glycoprotein expressed on B cells surface that activates antigen presenting cells [1]. BLK and BANK1 are components of B cells…Abstract Number: 0335 • ACR Convergence 2022
Multiplexed Mass Cytometry of Cutaneous Lupus Erythematosus and Dermatomyositis Skin: An In-depth B Cell Directed Immunoprofile
Background/Purpose: Cutaneous lupus erythematosus (CLE) and dermatomyositis (DM) are both characterized histologically by interface dermatitis with a perivascular and periadnexal lymphocytic infiltrate, requiring clinical correlation…Abstract Number: 1629 • ACR Convergence 2022
AUR200: An Improved BAFF/APRIL Inhibitor with Increased Potency and Safety for the Treatment of B Cell-Mediated Diseases
Background/Purpose: AUR200 targets both B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), which are key mediators in the pathogenesis of B cell-mediated autoimmune…Abstract Number: 0351 • ACR Convergence 2022
The Effect of Belimumab to Achieve Low Disease Activity or Remission Based on SLE-DAS in Systemic Lupus Erythematosus: A Single-center Retrospective Study
Background/Purpose: Low disease activity (LDA) and remission in patients with systemic lupus erythematosus (SLE) can reduce organ damage accrual and improve prognosis. We investigated the…Abstract Number: 1631 • ACR Convergence 2022
Phospholipase D 4 Is a Novel Surface Marker of a Distinctive B Cell Population Overlapping with Double Negative 2 B Cells
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by various autoantibodies. In particular, targeting autoreactive B cells could be a promising therapy with…Abstract Number: 0527 • ACR Convergence 2022
Rituximab as Maintenance Therapy for ANCA-associated Vasculitides: Pooled Analysis and Long-term Outcome of MAINRITSAN Trials
Background/Purpose: Maintenance therapy after induction of remission has been shown to reduce relapse rate and mortality in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The three MAINRITSAN…Abstract Number: 1632 • ACR Convergence 2022
Novel Autoantibodies Identify Sjögren’s Disease in Patients Lacking Serum IgG Specific for Ro/SS-A and La/SS-B
Background/Purpose: Classification of Sjögren's disease (SjD) requires either Ro/SS-A autoantibodies or minor salivary gland biopsy positive for focal lymphocytic infiltrates. Up to 40% of SjD…Abstract Number: 0624 • ACR Convergence 2022
CD20+ T Cells in the Synovial Fluid of Patients with Rheumatoid Arthritis Suggest a Role for Trogocytosis in Disease Pathogenesis and Activity
Background/Purpose: Approximately 1-2% of peripheral blood T cells express CD20, a marker of the B lineage, in both healthy individuals and patients with rheumatoid arthritis…Abstract Number: 1677 • ACR Convergence 2022
Chimeric Autoantigen-T Cell Receptor (CATCR)-T Cell Therapies to Selectively Target Autoreactive B Cells
Background/Purpose: Chimeric antigen receptor (CAR)-T cell therapies have revolutionized the treatment of cancer and can be curative. CD19-targeted CAR-T cells hold promise for the treatment…Abstract Number: 0644 • ACR Convergence 2022
Long-lived Plasma Cells in the Lupus Bone Marrow Are Imprinted by Interferon
Background/Purpose: Systemic lupus erythematous (SLE) is a complex autoimmune disorder with heterogeneous disease presentation and a multi-pronged pathogenesis. Although autoreactive plasma cells (PC) play a…Abstract Number: 1869 • ACR Convergence 2022
Looking for BlyS(BAFF) in Juvenile Dermatomyositis: A New Biomarker of Disease Activity
Background/Purpose: B Cell Activating Factor (BAFF) is a cytokine that drives B Cell proliferation and maturation. B Cells remain an important factor in JDM immune…Abstract Number: 0720 • ACR Convergence 2022
Risk-Benefit Assessment of Primary Prophylaxis for Pneumocystis Pneumonia in Patents with Rheumatic Diseases Exposed to Rituximab: A Multicenter Cohort Study
Background/Purpose: Although previous studies suggested that primary prophylaxis for pneumocystis pneumonia (PJP) during rituximab treatment could be beneficial, it is uncertain whether this strategy should…
ACR Meeting Abstracts